AN OPEN-LABEL, SINGLE-ARM PHASE IIIb STUDY IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION OR MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TO EVALUATE THE USABILITY OF LUCENTIS PREFILLED SYRINGE 0.5 mg

Trial Profile

AN OPEN-LABEL, SINGLE-ARM PHASE IIIb STUDY IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION OR MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TO EVALUATE THE USABILITY OF LUCENTIS PREFILLED SYRINGE 0.5 mg

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 20 Jun 2016 Status changed from recruiting to completed.
    • 10 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top